{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:22:17Z","timestamp":1784604137907,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018568","name":"Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province","doi-asserted-by":"publisher","award":["202053-74"],"award-info":[{"award-number":["202053-74"]}],"id":[{"id":"10.13039\/501100018568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018568","name":"Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province","doi-asserted-by":"publisher","award":["202053-75"],"award-info":[{"award-number":["202053-75"]}],"id":[{"id":"10.13039\/501100018568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370925"],"award-info":[{"award-number":["81370925"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["[81561128020\u2013NHMRC APP1112767"],"award-info":[{"award-number":["[81561128020\u2013NHMRC APP1112767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adiposity and elevated inflammation are two hallmarks of hyperglycemia. However, it is unknown whether clustering of elevated inflammation and adiposity interact act on diabetogenesis and lead to a greater risk for incident type 2 diabetes\u00a0(T2D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adiposity was indicated by body mass index, waist circumference and ultrasonography-measured fatty liver degrees. Elevated inflammation was indicated as high-sensitivity C-reactive protein levels\u2009\u2265\u20092\u00a0mg\/L. Time-to-event survival analyses were conducted to investigate the joint effect of adiposity and inflammation on incident T2D on both multiplicative and additive scales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 82,172 non-diabetic participants from a prospective cohort in China, 14,278 T2D occurred over a median follow-up of 11\u00a0years. In the multivariable-adjusted model, elevated inflammation [1.12 (1.08\u20121.16)] and adiposity [1.76 (1.69\u20121.83) for overweight\/obesity, 1.49 (1.44\u20121.55) for central obesity, and 2.02 (1.95\u20122.09) for fatty liver] were significantly associated with incident diabetes. Higher adiposity-associated risks and incidence rates of diabetes were observed with elevated inflammation. When studying the joint effect, the adjusted HRs were 1.77 (1.69\u20121.85) for overweight\/obesity, 1.14 (1.06\u20121.23) for elevated inflammation, and 2.08 (1.97\u20122.19) for their joint effect, with a relative excess risk due to interaction of 0.17 (0.05\u20120.28). The attributable proportions were 71.30% for overweight\/obesity, 12.96% for elevated inflammation, and 15.74% for their interaction. Similar results were observed when adiposity was assessed as waist circumference or fatty liver.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adiposity and elevated inflammation synergically lead to greater risks of incident diabetes than addition of each individual exposure. Strategies simultaneously targeting both risks should produce more benefits for diabetes prevention than through initiatives directed at each separate risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-02067-0","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T18:01:59Z","timestamp":1703095319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combined effect of adiposity and elevated inflammation on incident type 2 diabetes: a prospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Dan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"2067_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"24","key":"2067_CR2","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, Zhang X, Li C, Huang Z, Sun X, et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"key":"2067_CR3","doi-asserted-by":"publisher","first-page":"108072","DOI":"10.1016\/j.diabres.2020.108072","volume":"162","author":"R Williams","year":"2020","unstructured":"Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besan\u00e7on S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas 9th edition. Diabetes Res Clin Pract. 2020;162:108072.","journal-title":"Diabetes Res Clin Pract"},{"key":"2067_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10338","author":"C Jiang","year":"2022","unstructured":"Jiang C, Cifu AS, Sam S. Obesity and weight management for prevention and treatment of type 2 diabetes. JAMA. 2022. https:\/\/doi.org\/10.1001\/jama.2022.10338.","journal-title":"JAMA"},{"issue":"2","key":"2067_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98\u2013107.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2067_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31\u201355.","journal-title":"Immunity"},{"issue":"12","key":"2067_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-019-0213-9","volume":"19","author":"MY Donath","year":"2019","unstructured":"Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019;19(12):734\u201346.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2067_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00125-016-3873-z","volume":"59","author":"MY Donath","year":"2016","unstructured":"Donath MY. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia. 2016;59(4):679\u201382.","journal-title":"Diabetologia"},{"issue":"3","key":"2067_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327\u201334.","journal-title":"JAMA"},{"issue":"8","key":"2067_CR10","doi-asserted-by":"publisher","first-page":"e3446","DOI":"10.1002\/dmrr.3446","volume":"37","author":"X Yang","year":"2021","unstructured":"Yang X, Tao S, Peng J, Zhao J, Li S, Wu N, Wen Y, Xue Q, Yang CX, Pan XF. High-sensitivity C-reactive protein and risk of type 2 diabetes: a nationwide cohort study and updated meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3446.","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"2067_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2337\/dc15-0221","volume":"38","author":"VS Effoe","year":"2015","unstructured":"Effoe VS, Correa A, Chen H, Lacy ME, Bertoni AG. High-sensitivity c-reactive protein is associated with incident type 2 diabetes among african americans: the jackson heart study. Diabetes Care. 2015;38(9):1694\u2013700.","journal-title":"Diabetes Care"},{"issue":"3","key":"2067_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","volume":"52","author":"J Spranger","year":"2003","unstructured":"Spranger J, Kroke A, M\u00f6hlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812\u20137.","journal-title":"Diabetes"},{"issue":"6","key":"2067_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00125-009-1338-3","volume":"52","author":"CC Lee","year":"2009","unstructured":"Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, Luben R, Bingham S, Khaw KT, Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52(6):1040\u20137.","journal-title":"Diabetologia"},{"issue":"4","key":"2067_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.2337\/dc09-1679","volume":"33","author":"A Bertoni","year":"2010","unstructured":"Bertoni A, Burke G, Owusu J, Carnethon M, Vaidya D, Barr R, Jenny N, Ouyang P, Rotter J. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010;33(4):804\u201310.","journal-title":"Diabetes Care"},{"issue":"10","key":"2067_CR15","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.2337\/diacare.26.10.2754","volume":"26","author":"S Nakanishi","year":"2003","unstructured":"Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26(10):2754\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"2067_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/dc12-0702","volume":"36","author":"X Wang","year":"2013","unstructured":"Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166\u201375.","journal-title":"Diabetes Care"},{"issue":"1","key":"2067_CR17","first-page":"83","volume":"15","author":"BF Zhou","year":"2002","unstructured":"Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults\u2013study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83\u201396.","journal-title":"Biomed Environ Sci"},{"issue":"2","key":"2067_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.atherosclerosis.2008.03.001","volume":"201","author":"Y Bao","year":"2008","unstructured":"Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X, Zhu J, Lu H, Jia W, Xiang K. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis. 2008;201(2):378\u201384.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2067_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","volume":"52","author":"J Xu","year":"2021","unstructured":"Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, Meng X, Wu S, Wang Y. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke. 2021;52(1):103\u201310.","journal-title":"Stroke"},{"issue":"3","key":"2067_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107(3):499\u2013511.","journal-title":"Circulation"},{"issue":"6","key":"2067_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","volume":"67","author":"P Ridker","year":"2016","unstructured":"Ridker P. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"2067_CR22","first-page":"S15","volume":"44","author":"Classification and Diagnosis of Diabetes","year":"2021","unstructured":"Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-s33.","journal-title":"Diabetes Care"},{"issue":"4","key":"2067_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3945\/ajcn.116.144832","volume":"105","author":"S Huang","year":"2017","unstructured":"Huang S, Li J, Shearer GC, Lichtenstein AH, Zheng X, Wu Y, Jin C, Wu S, Gao X. Longitudinal study of alcohol consumption and HDL concentrations: a community-based study. Am J Clin Nutr. 2017;105(4):905\u201312.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2067_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"key":"2067_CR25","doi-asserted-by":"publisher","first-page":"k4641","DOI":"10.1136\/bmj.k4641","volume":"363","author":"Z Shan","year":"2018","unstructured":"Shan Z, Li Y, Zong G, Guo Y, Li J, Manson J, Hu F, Willett W, Schernhammer E, Bhupathiraju S. Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses. BMJ (Clinical research ed). 2018;363:k4641.","journal-title":"BMJ (Clinical research ed)"},{"issue":"5","key":"2067_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/EDE.0000000000000096","volume":"25","author":"TJ VanderWeele","year":"2014","unstructured":"VanderWeele TJ, Tchetgen Tchetgen EJ. Attributing effects to interactions. Epidemiology. 2014;25(5):711\u201322.","journal-title":"Epidemiology"},{"issue":"7","key":"2067_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10654-005-7835-x","volume":"20","author":"T Andersson","year":"2005","unstructured":"Andersson T, Alfredsson L, K\u00e4llberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20(7):575\u20139.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"2067_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"2","key":"2067_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","volume":"49","author":"A Ramachandran","year":"2006","unstructured":"Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289\u201397.","journal-title":"Diabetologia"},{"issue":"10267","key":"2067_CR30","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","volume":"396","author":"J Chan","year":"2021","unstructured":"Chan J, Lim L, Wareham N, Shaw J, Orchard T, Zhang P, Lau E, Eliasson B, Kong A, Ezzati M, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet (London, England). 2021;396(10267):2019\u201382.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2067_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003767","volume":"18","author":"X Li","year":"2021","unstructured":"Li X, Wang M, Song Y, Ma H, Zhou T, Liang Z, Qi L. Obesity and the relation between joint exposure to ambient air pollutants and incident type 2 diabetes: a cohort study in UK Biobank. PLoS Med. 2021;18(8): e1003767.","journal-title":"PLoS Med"},{"issue":"11","key":"2067_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.116.309279","volume":"119","author":"CA Pope 3rd","year":"2016","unstructured":"Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O\u2019Toole T. Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation. Circ Res. 2016;119(11):1204\u201314.","journal-title":"Circ Res"},{"issue":"23","key":"2067_CR33","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739\u201348.","journal-title":"Circulation"},{"issue":"12","key":"2067_CR34","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","volume":"14","author":"A Rissanen","year":"2012","unstructured":"Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1\u03b2 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14(12):1088\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"2067_CR35","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A, V\u00f8lund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517\u201326.","journal-title":"N Engl J Med"},{"issue":"21","key":"2067_CR36","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","volume":"71","author":"BM Everett","year":"2018","unstructured":"Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"2067_CR37","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dcS15-3015","volume":"39","author":"RM Pollack","year":"2016","unstructured":"Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39(Suppl 2):S244-252.","journal-title":"Diabetes Care"},{"issue":"10077","key":"2067_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skj\u00f8th TV, Manning LS, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"12","key":"2067_CR39","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2337\/dc17-1116","volume":"40","author":"WH Herman","year":"2017","unstructured":"Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, et al. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017;40(12):1668\u201377.","journal-title":"Diabetes Care"},{"issue":"2","key":"2067_CR40","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2337\/dc21-1136","volume":"45","author":"S Kullmann","year":"2022","unstructured":"Kullmann S, Hummel J, Wagner R, Dannecker C, Vosseler A, Fritsche L, Veit R, Kantartzis K, Machann J, Birkenfeld AL, et al. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care. 2022;45(2):398\u2013406.","journal-title":"Diabetes Care"},{"issue":"7086","key":"2067_CR41","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nature04634","volume":"440","author":"N Houstis","year":"2006","unstructured":"Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944\u20138.","journal-title":"Nature"},{"issue":"8","key":"2067_CR42","first-page":"863","volume":"44","author":"RH Unger","year":"1995","unstructured":"Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications Diabetes. 1995;44(8):863\u201370.","journal-title":"Genetic and clinical implications Diabetes"},{"issue":"12","key":"2067_CR43","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nri2449","volume":"8","author":"GS Hotamisligil","year":"2008","unstructured":"Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923\u201334.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2067_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179\u201388.","journal-title":"Nat Med"},{"issue":"4","key":"2067_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-725.e716.","journal-title":"Gastroenterology"},{"issue":"5","key":"2067_CR46","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","volume":"54","author":"S Haffner","year":"2005","unstructured":"Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566\u201372.","journal-title":"Diabetes"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02067-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:50:18Z","timestamp":1703148618000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02067-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2067"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02067-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current subanalysis of the Kailuan Study was approved by the Kailuan General Hospital Ethics Committee, China (2006\u201305), and the Human Research Ethics Committee of Edith Cowan University (2021\u201303159\u2013BALMER). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}